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In recent years antiretroviral availability and access has
become more prevalent in resource poor settings, whilst
the availability of access to HIV-1 drug resistance testing
remains limited and patients are often started on therapy
or switched when failing without a resistance test. Proviral
DNA has been proposed as a source of archived resistance
mutations. We investigated the feasibility of using proviral
DNA to detect previously documented plasma resistance
mutations.
Amplification and sequencing of pol from proviral DNA
derived from buffy coat (BCL), buffy coat dried on filter
paper (BCS) or dried blood spots (DBS) was performed
using an in-house assay.
Only 2/20 samples were amplified from long term stored
buffy coat (>1 year) compared to at least one prospective
sample from 10/20 patients. Six patients had a plasma
viral load (PVL) <40 cp/ml at time of sampling, though
4/6 only become undetectable on the most recent sample,
2/4 had been undetectable for 149 and 819 days respec-
tively. The remaining 6 patients had detectable PVL
(median 3.1 log10 cp/ml, range: 1.7–6.2 log10 cp/ml). In
contrast, 21/28 (75%) of samples which failed to amplify
were <40 cp/ml, 2 had become undetectable in the most
recent sample and 19 had been undetectable for a median
of 577 days (range: 32–2481 days).
6/10 BCL samples showed none of the previously
documented resistance for those patients, 3/10 showed
some of the previously known mutations and only 1/10
showed all historic resistance, though this patient had
only one documented mutation (K103N). For the BCS
samples 3/4 showed none of the documented resistance,
1/4 harboured the previously known mutations (M184V,
K103N). 3/6 of the DBS had none of the previously
documented resistance, 2/6 showed some of the known
mutations and 1/6 showed both known resistance muta-
tions (M41L, T215S). In patients where multiple specimen
types were amplified, 3/5 showed differences in mutations
detected between sample types, with 2/5 correlating but
having no mutations detected in any specimens.
In patients with undetectable PVL, particularly those
undetectable for long periods, it was difficult to sequence
archived DNA. Concordance between different specimen
types was variable as was concordance with previously
documented mutations. Historic resistance reports
remain important in the clinical management of patients
on antiretroviral therapy, though proviral DNA testing
may be useful in patients where historic reports are not
available.
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